CELU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CELU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Celularity's enterprise value is $126.15 Mil. Celularity's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $14.79 Mil. Therefore, Celularity's EV-to-Revenue for today is 8.53.
The historical rank and industry rank for Celularity's EV-to-Revenue or its related term are showing as below:
During the past 3 years, the highest EV-to-Revenue of Celularity was 95.98. The lowest was 6.40. And the median was 13.73.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-11), Celularity's stock price is $2.95. Celularity's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.84. Therefore, Celularity's PS Ratio for today is 3.50.
The historical data trend for Celularity's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celularity Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
EV-to-Revenue | - | 29.55 | 13.56 |
Celularity Quarterly Data | ||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 19.16 | 13.56 | 9.86 | 10.25 | 7.02 |
For the Biotechnology subindustry, Celularity's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Celularity's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Celularity's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Celularity's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 126.154 | / | 14.788 | |
= | 8.53 |
Celularity's current Enterprise Value is $126.15 Mil.
Celularity's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celularity (NAS:CELU) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Celularity's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 2.95 | / | 0.842 | |
= | 3.50 |
Celularity's share price for today is $2.95.
Celularity's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Celularity's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kok Thay Lim | director | 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250 |
Robert J Hariri | director, officer: Chief Executive Officer | 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924 |
Ling Geoffrey M.d. | director | C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080 |
Berhad Genting | 10 percent owner | 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250 |
Adrian Kilcoyne | officer: See Remarks | 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010 |
John Sculley | director | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Kyle Fletcher | officer: General Counsel | CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932 |
Peter Diamandis | director | 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292 |
Dean C Kehler | director | C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Marc Mazur | director | 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019 |
Diane L. Parks | director | 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
Bradley Glover | director, officer: Chief Technology Officer | C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932 |
Stephen Brigido | officer: Pres, Functional Regeneration | C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932 |
Anne Jones | director, officer: Chief Business Officer | C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932 |
From GuruFocus
By Business Wire Business Wire • 01-11-2023
By Stock market mentor Stock market mentor • 01-06-2023
By Business Wire Business Wire • 12-05-2022
By PRNewswire PRNewswire • 01-11-2023
By PRNewswire • 07-19-2023
By Marketwired • 08-29-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 05-19-2023
By GuruFocus Research GuruFocus Editor • 11-30-2022
By Stock market mentor Stock market mentor • 02-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.